Carcinoid Tumor Market Research Report – Global Forecast till 2023

Carcinoid Tumor Market Research Report, Site (Lung, Gastrointestinal), Diagnosis (Serology, Imaging, Biopsy), Treatment (Chemotherapy, Radiotherapy), End Users (Hospital & Clinics, Academic Institutes, Research Organization) - Global Forecast Till 2023

ID: MRFR/Pharma/3386-HCR | | Region: Global | 90 pages

 


Market Scenario:
Carcinoid tumor is a type of the neuroendocrine tumor. A neuroendocrine tumor develops in the body’s neuroendocrine system, which is made up of cells that are a combination of hormone-producing endocrine cells and nerve cells. The most common site of carcinoid tumors is GI (gastrointestinal) tract and lungs. The other sites for the development of the carcinoid tumors is inclusive of the pancreas, testicles, and ovaries. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the United States diagnose with the carcinoid tumor in their lung. Thus, the prevalence of the carcinoid tumor is expected to drive the market. In 2016, American Society of Clinical Oncology (ASCO) published a report stating that the people who were diagnosed with carcinoid tumor were in their early 60s. Additionally, according to the report of WHO published in 2015, the geriatric population is expected to double and reach 2.1 billion by 2050. Thus, the growing geriatric population along with rising healthcare expenditure is set to boost the market growth during the forecast period. However, lack of awareness, treatment cost and related side effects may restrain the market growth during the forecast period. 


The global carcinoid tumor market is expected to grow at an approximate of CAGR of 10.5% during forecast period. 


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers 


Figure 1:- Global carcinoid tumor market share, by region
Carcinoid Tumor Market


Sources: WHO, annual reports, press release, white paper, and company presentation


 


Segmentation


The global carcinoid tumor market is segmented on the basis of site, diagnosis, treatment, and end users.


On the basis of site, the market is segmented into gastrointestinal, lung, and others. Furthermore, the gastrointestinal segment is sub-segmented into rectum, small intestine, appendix, and others. The lung segmented is sub-segmented into typical, atypical, and others.


On the basis of diagnosis, the market is segmented into serology, imaging, biopsy, and others. The serology segment is sub-segmented into blood test, urine test, molecular test, and others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and others.


On the basis of treatment, the market is segmented into surgery, chemotherapy, radiotherapy, and others. The surgery segment is sub-segmented into local excision, radiofrequency ablation (RFA), and others.


On the basis of end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.


 


Regional Analysis


America dominates the global carcinoid tumor market owing to a well-developed healthcare sector and huge patient population. Apart from this, increasing healthcare expenditure and presence of developed economies within the region are adding fuel to the growth of the market in America.


Europe is the second leading region in the global carcinoid tumor market, which is followed by Asia Pacific. Availability of funds for research, huge patient population and government support for research & development are projected to drive the market. According to the National Health Service in 2015, each year about 1,200 people diagnose with carcinoid tumor in the UK.


Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies like India and China, and the presence of huge opportunity in the market. Moreover, there are huge opportunities within the region for the growth of the untapped market.


On the other hand, the Middle East & Africa accounts the least share of the global carcinoid tumor market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.


 


Research Methodology



Carcinoid Tumor Market-


Sources: WHO, annual reports, press release, white paper, and company presentation 


Key Players in the Global Carcinoid Tumor Market


Some of the key players in the global carcinoid tumor market are Novartis AG (Europe), Amgen Inc. (U.S.), Boehringer Ingelheim GmbH (Europe), AVEO Pharmaceuticals, Inc. (U.S.), Chiasma, Inc. (U.S.), Aegis Therapeutics, LLC (U.S.), CRINETICS PHARMACEUTICALS (U.S.), Delcath Systems Inc. (U.S.), Exelixis, Inc. (U.S.), and others.



Frequently Asked Questions (FAQ) :


carcinoid tumor market CAGR would be 10.5% during the forecast period.

The Americas would take charge of the carcinoid tumor market.

The Asia Pacific region would be the fastest-growing in the carcinoid tumor market.

The players involved in the carcinoid tumor market are Amgen Inc. (U.S.), Novartis AG (Europe), Exelixis, Inc. (U.S.), AVEO Pharmaceuticals, Inc. (U.S.), Boehringer Ingelheim GmbH (Europe), Aegis Therapeutics, LLC (U.S.), Chiasma, Inc. (U.S.), Delcath Systems Inc. (U.S.), CRINETICS PHARMACEUTICALS (U.S.), and others.

The carcinoid tumor market report includes diagnoses like a biopsy, imaging, serology, and others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Carcinoid Tumor Market, by Site

6.1 Introduction

6.2 Gastrointestinal

Market Estimates & Forecast, 2017 – 2023

6.2.1 Rectum

6.2.2 Small Intestine

6.2.3 Appendix

6.2.4 Others

6.3 Lung

Market Estimates & Forecast, 2017 – 2023

6.3.1 Typical

6.3.2 Atypical

6.3.3 Others

6.4 Others

Chapter 7. Global Carcinoid Tumor Market, by Diagnosis

7.1 Introduction

7.2 Serology

Market Estimates & Forecast, 2017 – 2023

7.2.1 Blood Test

7.2.2 Urine Test

7.2.3 Molecular Test

7.2.4 Others

7.3 Imaging

Market Estimates & Forecast, 2017 – 2023

7.3.1 X ray

7.3.2 CT Scan

7.3.3 PET Scan

7.3.4 Others

7.4 Biopsy

Market Estimates & Forecast, 2017 – 2023

7.5 Others

Market Estimates & Forecast, 2017 – 2023

Chapter 8. Global Carcinoid Tumor Market, by Treatment

8.1 Introduction

8.2 Surgery

Market Estimates & Forecast, 2017 – 2023

8.2.1 Local excision

8.2.2 Radiofrequency Ablation (RFA)

8.2.3 Others

8.3 Chemotherapy

Market Estimates & Forecast, 2017 – 2023

8.4 Radiotherapy

Market Estimates & Forecast, 2017 – 2023

Chapter 9 Global Carcinoid Tumor Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2017 – 2023

9.3 Academic Institutes

Market Estimates & Forecast, 2017 – 2023

9.4 Research Organization

Market Estimates & Forecast, 2017 – 2023

Chapter 10. Global Carcinoid Tumor Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 US

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Novartis AG

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials Overview

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 Amgen Inc.

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Boehringer Ingelheim GmbH

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 AVEO Pharmaceuticals, Inc.

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Chiasma, Inc.

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis
12.6 Aegis Therapeutics, LLC

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis
12.7 CRINETICS PHARMACEUTICALS

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Delcath Systems Inc.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Exelixis, Inc.

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical industry

Chapter 14 Appendix

LIST OF TABLES

Table 1 Cancer Industry Synopsis, 2017 – 2023

Table 2 Global Carcinoid Tumor Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Global Carcinoid Tumor Market by Region, 2017 – 2023, (USD Million)

Table 4 Global Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 5 Global Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 6 Global Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Global Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 8 North America Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 9 North America Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 12 US Market by Tumor Market by Site, 2017 – 2023, (USD Million)

Table 13 US Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 US Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 16 Canada Market Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 17 Canada Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 20 South America Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 21 South America Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 22 South America Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 24 Europe Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 25 Europe Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 28 Western Europe Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 29 Western Europe Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Carcinoid Tumor Market by Traetment, 2017 – 2023, (USD Million)

Table 31 Western Europe Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Carcinoid Tumor Market by Site, 2017 – 2023, (USD Million)

Table 41 Middle East & Africa Carcinoid Tumor Market by Diagnosis, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Carcinoid Tumor Market by Treatment, 2017 – 2023, (USD Million)

Table 43 Middle East & Africa Carcinoid Tumor Market by End Users, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Carcinoid Tumor Market

Figure 3 Segmentation Market Dynamics for Global Carcinoid Tumor Market

Figure 4 Global Carcinoid Tumor Market Share, by Site 2016

Figure 5 Global Carcinoid Tumor Market Share, by Diagnosis 2016

Figure 6 Global Carcinoid Tumor Market Share, by Treatment 2016

Figure 7 Global Carcinoid Tumor Market Share, by End Users, 2016

Figure 8 Global Carcinoid Tumor Market Share, by Region, 2016

Figure 9 North America Carcinoid Tumor Market Share, by Country, 2016

Figure 10 Europe Carcinoid Tumor Market Share, by Country, 2016

Figure 11 Asia Pacific Carcinoid Tumor Market Share, by Country, 2016

Figure 12 Middle East & Africa Carcinoid Tumor Market Share, by Country, 2016

Figure 13 Global Carcinoid Tumor Market: Company Share Analysis, 2016 (%)

Figure 14 Novartis AG: Key Financials

Figure 15 Novartis AG: Segmental Revenue

Figure 16 Novartis AG: Geographical Revenue

Figure 17 Amgen Inc.: Key Financials

Figure 18 Amgen Inc.: Segmental Revenue

Figure 19 Amgen Inc.: Geographical Revenue

Figure 20 Boehringer Ingelheim GmbH: Key Financials

Figure 21 Boehringer Ingelheim GmbH: Segmental Revenue

Figure 22 Boehringer Ingelheim GmbH: Geographical Revenue

Figure 23 AVEO Pharmaceuticals, Inc.: Key Financials

Figure 24 AVEO Pharmaceuticals, Inc.: Segmental Revenue

Figure 25 AVEO Pharmaceuticals, Inc.: Geographical Revenue

Figure 26 Chiasma, Inc.: Key Financials

Figure 27 Chiasma, Inc.: Segmental Revenue

Figure 28 Chiasma, Inc.: Geographical Revenue

Figure 29 Aegis Therapeutics, LLC: Key Financials

Figure 30 Aegis Therapeutics, LLC.: Segmental Revenue

Figure 31 Aegis Therapeutics, LLC.: Geographical Revenue

Figure 32 CRINETICS PHARMACEUTICALS: Key Financials

Figure 33 CRINETICS PHARMACEUTICALS: Segmental Revenue

Figure 34 CRINETICS PHARMACEUTICALS: Geographical Revenue

Figure 35 Delcath Systems Inc.: Geographical Revenue

Figure 36 Delcath Systems Inc.: Segmental Revenue

Figure 37 Delcath Systems Inc: Geographical Revenue

Figure 38 Exelixis, Inc.: Geographical Revenue

Figure 39 Exelixis, Inc.:Segmental Revenue

Figure 40 Exelixis, Inc.: Geographical Revenue